Cannabinoids for the Treatment of Opioid Use Disorder: Where is the Evidence?
- PMID: 32909980
- PMCID: PMC7986228
- DOI: 10.1097/ADM.0000000000000711
Cannabinoids for the Treatment of Opioid Use Disorder: Where is the Evidence?
Abstract
With the growing public interest in the potential therapeutic benefits of cannabis and cannabinoids in the treatment of opioid use disorder (OUD), some states have now either added or proposed to add OUD as an indication for their state's medical marijuana program. However, these initiatives are based on weak evidence which at present do not support the listing of cannabis or cannabinoids as a treatment for OUD. Nevertheless, studying the potential therapeutic applications of carefully chosen components of cannabis or cannabinoids to treat specific aspects of OUD is not without scientific merit. Given the high rates of treatment discontinuation among those taking medications for OUD, interventions that further improve clinical outcomes are especially needed. The potential therapeutic applications of cannabis and cannabinoids in the treatment of OUD are worthy of further study, but it should be conducted with the same rigor that we expect of all pharmaceutical products. Until we have more research to show their efficacy, policy makers and clinicians should refrain from portraying cannabis and cannabinoids as evidence-based treatments for OUD.
Copyright © 2020 American Society of Addiction Medicine.
Conflict of interest statement
Similar articles
-
Association of State Policies Allowing Medical Cannabis for Opioid Use Disorder With Dispensary Marketing for This Indication.JAMA Netw Open. 2020 Jul 1;3(7):e2010001. doi: 10.1001/jamanetworkopen.2020.10001. JAMA Netw Open. 2020. PMID: 32662844 Free PMC article.
-
Cannabis and Cannabinoids for Chronic Pain.Curr Rheumatol Rep. 2017 Oct 5;19(11):67. doi: 10.1007/s11926-017-0693-1. Curr Rheumatol Rep. 2017. PMID: 28983880 Review.
-
Comprehensive Review of Medicinal Marijuana, Cannabinoids, and Therapeutic Implications in Medicine and Headache: What a Long Strange Trip It's Been ….Headache. 2015 Jun;55(6):885-916. doi: 10.1111/head.12570. Epub 2015 May 25. Headache. 2015. PMID: 26015168 Review.
-
Understanding Cannabis-Based Therapeutics in Sports Medicine.Sports Health. 2020 Nov/Dec;12(6):540-546. doi: 10.1177/1941738120956604. Epub 2020 Sep 16. Sports Health. 2020. PMID: 32936058 Free PMC article. Review.
-
Medical cannabis and cannabinoids in rheumatology: where are we now?Expert Rev Clin Immunol. 2019 Oct;15(10):1019-1032. doi: 10.1080/1744666X.2019.1665997. Expert Rev Clin Immunol. 2019. PMID: 31512536 Review.
Cited by
-
The Therapeutic Potential of Cannabidiol in Revolutionising Opioid Use Disorder Management.Cureus. 2023 Dec 16;15(12):e50634. doi: 10.7759/cureus.50634. eCollection 2023 Dec. Cureus. 2023. PMID: 38226097 Free PMC article. Review.
-
Prevalence of Cannabis Use and Cannabis Route of Administration among Massachusetts Adults in Buprenorphine Treatment for Opioid Use Disorder.Subst Use Misuse. 2022;57(7):1104-1110. doi: 10.1080/10826084.2022.2063899. Epub 2022 Apr 11. Subst Use Misuse. 2022. PMID: 35410577 Free PMC article.
-
Cannabidiol Effect on Cue-Induced Craving for Individuals with Opioid Use Disorder Treated with Buprenorphine: A Small Proof-of-Concept Open-Label Study.Integr Med Rep. 2022 Aug 1;1(1):157-163. doi: 10.1089/imr.2022.0070. Epub 2022 Aug 26. Integr Med Rep. 2022. PMID: 36105269 Free PMC article.
-
A national population-based study of cannabis use and correlates among U.S. veterans prescribed opioids in primary care.BMC Psychiatry. 2023 Mar 17;23(1):177. doi: 10.1186/s12888-023-04648-5. BMC Psychiatry. 2023. PMID: 36927526 Free PMC article.
-
Cannabis donation as a harm reduction strategy: a case study.Harm Reduct J. 2024 Mar 6;21(1):58. doi: 10.1186/s12954-024-00974-3. Harm Reduct J. 2024. PMID: 38449029 Free PMC article.
References
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical